Imaging Efficacy of [ 18 F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath—A Phase 3, Prospective Multicenter Study
Journal of Nuclear Medicine · 2025
DOI: 10.2967/jnumed.124.269266 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Stefano Fanti und 16 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine, IRCCS AOU di Bologna, Bologna, Italy; stefano.fanti@aosp.bo.it. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Improved diagnostic accuracy in patients with prostate cancer at first biochemical recurrence (BCR) with low prostate-specific antigen (PSA) levels is needed. This prospective study (GuidePath; NCT04838613) aimed to evaluate the imaging performance of the prostate-specific membrane antigen (PSMA)-targeted PET radiotracer [18F]CTT1057 to detect PSMA-positive lesions in patients diagnosed predominantly at first BCR.
Methods
Eligible patients had a PSA of 0.2 ng/mL or greater after radical prostatectomy or an increase in PSA level of at least 2 ng/mL above nadir after radiation therapy. Patients received 370 MBq of [18F]CTT1057 and 150 MBq of [68Ga]Ga-PSMA-11 and underwent PET/CT 90 min (±30 min) and 50-100 after injection, respectively. [18F]CTT1057 images were assessed by 3 independent readers blinded to all clinical information. Coprimary endpoints were region-level correct localization rate (CLR) and patient-level positive predictive value (PPV) of [18F]CTT1057 to detect PSMA-positive lesions and were compared with a hierarchical composite truth standard (CTS). The CTS comprised 3 levels of standard-of-truth procedures (in order of priority): histopathology (CTS level 1); imaging, including at least 1 contrast-enhanced CT scan and 1 [68Ga]Ga-PSMA-11 PET/CT scan (CTS level 2); and a decrease in PSA level of 50% or greater 3 mo after radiation therapy (CTS level 3). For study success, the lower-bound 95% CI had to surpass 50% for region-level CLR and 20% for patient-level PPV for at least 2 of the 3 [18F]CTT1057 PET/CT readers.
Results
Of 202 patients screened, 161 were evaluable for efficacy. Among these, 93.2% were experiencing their first BCR, 96.3% had received radical prostatectomy as initial definitive therapy, and baseline median PSA level was 0.4 ng/mL (interquartile range, 0.3-0.8 ng/mL). The imaging standard of truth was used for 159-160 patients (99%) across the 3 readers. Both coprimary endpoints were met. Region-level CLR ranged from 65.2% to 75.0% (lower-bound 95% CI, 53.4%-62.1%), and patient-level PPV ranged from 64.6% to 76.5% (lower-bound 95% CI, 51.8%-62.5%). Conclusion: [18F]CTT1057 met the predefined thresholds for region-level CLR and patient-level PPV in a clinically relevant patient cohort predominantly at first BCR with low PSA levels. [18F]CTT1057 is an accurate PSMA-targeted PET radiotracer for BCR detection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine, IRCCS AOU di Bologna, Bologna, Italy; stefano.fanti@aosp.bo.it.
- Nuclear Medicine, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
- University of California San Francisco, San Francisco, California.
- Department of Urology and Martini-Klinik Prostate Cancer Center, University of Hamburg-Eppendorf, Hamburg, Germany.
- Clinic Hospital Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
- Department of Urology, Institut Paoli-Calmettes Cancer Centre, Marseille, France.
Zitieren
APA
Fanti, S., Robles Barba, J. J., Behr, S., Maurer, T., Paredes, P., Walz, J., Duch, J., Perdigo, M. S., Mainta, I. C., Bonnefoy, P. B., Coulanges, M., Tang, J., Seigne, C., Wilke, C., Catafau, A. M., Iagaru, A., & Aggarwal, R. (2025). Imaging Efficacy of [ 18 F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath—A Phase 3, Prospective Multicenter Study. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.269266
Vancouver
Fanti S, Robles Barba JJ, Behr S, Maurer T, Paredes P, Walz J, et al. Imaging Efficacy of [ 18 F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath—A Phase 3, Prospective Multicenter Study. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.269266
BibTeX
@article{Fanti2025,
author = {Fanti, Stefano and Robles Barba, Javier Jesus and Behr, Spencer and Maurer, Tobias and Paredes, Pilar and Walz, Jochen and Duch, Joan and Perdigo, Marc Simo and Mainta, Ismini Charis and Bonnefoy, Pierre Benoit and Coulanges, Medge and Tang, Jun and Seigne, Christelle and Wilke, Celine and Catafau, Ana M and Iagaru, Andrei and Aggarwal, Rahul},
title = {Imaging Efficacy of [ 18 F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath—A Phase 3, Prospective Multicenter Study},
journal = {Journal of Nuclear Medicine},
year = {2025},
doi = {10.2967/jnumed.124.269266}
}
EUVIMED